🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Treatment of Low-flow Venous Malformations With Electrosclerotherapy. Prospective Observational Study

Recruitingn/aAges 16 Years - anyAllIstituto Ortopedico Rizzoli
NCT06189092 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Venous malformations (MVs) are congenital abnormalities of the central or periphery caused by developmental errors at different stages of embryogenesis. Histologically they are characterized by large, venous-like vascular spaces. Scleroembolization constitutes the most widespread method in the treatment of venous malformations allowing good results with low invasiveness. Currently, Bleomycin (and its derivatives) is among the most widely used sclerosing agents for slow-flowing vascular malformations (venous and lymphatic malformations) because of the low rate of local serious adverse events such as swelling, necrosis, and nerve injury compared with others.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Diagnosis of low-flow venous malformations eligible for electrosclerotherapy * Non-indication for embolizing treatment * Previous treatments are not an exclusion factor, provided that at least 30 days have elapsed. Exclusion Criteria: * Previous treatment for \< 30 days * Pregnancy and lactation status * Patients of childbearing age without contraceptive use * Presence of metal synthetic media * COPD with FiO2 \< 30 mmHg * Impaired renal function with eGFR\<30 ml/min/1.73mq * Patients with Bleomycin intolerance or previous episodes of toxicity Bleomycin-related * Patients who have already received a cumulative dose of Bleomycin ≥100 mg * Patients who have undergone prior thoracic radiotherapy * Patients with a history of seizures and epilepsy
💊

What it tests

  • Bleomycin
📍

Where

1 site
Istituto Ortopedico Rizzoli
Bologna, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy